Saturday 17 October 2026
Export BIVI’s income statement to Excel — free account
BioVie Inc.
BIVI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 209.1% and free cash flow grew 26.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.20
0.07
+6.19%
Follow BIVI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(95.24%) | (80.94%) | (106.66%) | (151.06%) | |
| (77.26%) | (72.53%) | (94.65%) | (123.51%) | ||
ROIC |
0.00% | 0.00% | (513.12%) | (1,095.01%) | |
Return on Tangible Assets |
(76.13%) | (93.04%) | (131.44%) | (224.61%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.54) | (1.81) | (2.72) | (2.63) | |
Free Cash Flow |
(18.47) | (14.32) | (20.51) | (19.02) | |
| Other line items | |||||
Cash ROIC |
(37.01%) | (35.98%) | (71.45%) | (98.84%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(244.33) | (1,011.01) | (1,083.97) | (1,258.43) | |
Operating CF/Net income |
0.99 | 0.82 | 1.03 | 0.86 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.54) | (1.81) | (2.72) | (2.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates